CORRECTION article
Front. Bioeng. Biotechnol.
Sec. Biomaterials
Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1623425
Corrigendum: Advances in Doxorubicin-based Nano-drug Delivery System in Triple-negative Breast Cancer
Provisionally accepted
- 1Department of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, China
- 2Shenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In the published article, there was two errors.A correction has been made to Abstract.This sentence previously stated:“Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer.”The corrected sentence appears below:“Triple negative breast cancer (TNBC) is one of the most aggressive breast cancer.”Another correction has been made to Introduction, Paragraph one. This sentence previously stated:“Triple positive breast cancer (TPBC) is a specific type of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and accounts for approximately 15% of all breast cancer cases.”The corrected sentence appears below:“Triple negative breast cancer (TNBC) is a specific type of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and accounts for approximately 15% of all breast cancer cases.”The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Doxorubicin, nanocarriers, Triple negative breast cancer, Drug delivery, clinical
Received: 06 May 2025; Accepted: 12 May 2025.
Copyright: © 2025 Zeng, Luo, Gan, Zhang, Deng and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Weiwei Zeng, Department of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, China
Guihui Liu, Shenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.